Synthesis and Biological Evaluation of New Bisphosphonate–Dextran Conjugates Targeting Breast Primary Tumor
journal contributionposted on 19.02.2014, 00:00 by Evelyne Migianu-Griffoni, Imène Chebbi, Souad Kachbi, Maelle Monteil, Odile Sainte-Catherine, Frédéric Chaubet, Olivier Oudar, Marc Lecouvey
Bisphosphonates (BPs) have interesting antitumor effects as well in vitro as in vivo, despite their poor bioavailability in the organism after oral ingestion. To overcome this problem and reduce drug doses and secondary effects, we report the chemical synthesis of new bioconjugates. They were built with a nitrogen-containing BP as the drug covalently coupled to the carboxymethyldextran. This polysaccharide was used as a carrier, in order to increase BP lifetime in bloodstream and to target tumor cells which have a strong affinity with dextran. The efficiency of our vectorization system was biologically proved in vitro and in vivo on mammalian carcinoma models in mice.